Regarding TDF exposure, twelve, one and one patient(s) received TDF from the first, second and third trimester, respectively. The median duration of TDF exposure during pregnancy was 35 weeks (range: 5-39

weeks). HBV-DNA was assessed at delivery in 12 patients. Among these, 10 patients (83%) had HBV-DNA < 6 logIU/mL at delivery. Two cases of high HBV-DNA were associated with non-compliance and TDF discontinuation at week 9 of pregnancy. The median gestational age at delivery was 39 weeks (range: CT99021 34-40 weeks). No adverse events related to TDF and no cases of birth defects were observed. Five patients reported breastfeeding, and 3 of them breastfed while receiving TDF treatment without any consequence on the babies up to 1 year. No cases of positive HBsAg were observed in infants. Additionally, among 5 infants with anti-HBs testing, all were anti-HBs positive (84-308mIU/mL). Conclusions: In a HBV real-life cohort, TDF treatment from the first trimester of pregnancy was well tolerated. No cases of MTCT were observed. Moreover, no safety issues were reported for breastfeeding while on TDF up to 1 year. Disclosures: Nathalie Ganne-Carrie – Advisory Committees CP-690550 concentration or Review Panels: Roche, MSD; Speaking and Teaching: BMS, Gilead Xavier Causse – Board Membership: Gilead, BMS, MSD, Janssen-Cilag; Speaking and Teaching: Roche, Gilead, BMS, Janssen-Cilag Jean-Pierre H. Zarski – Advisory

Committees or Review Panels: BMS, Gilead, Janssen Cilag, BMS, Gilead, Janssen Cilag; Consulting: Roche, Scherring Plough, Novartis, Roche, Scherring Plough, Novartis; Speaking and Teaching: Siemens Fabien Zoulim – Advisory Committees or Review Panels: Gilead; Consulting:

Roche; Grant/Research Support: Gilead, Scynexis, Roche; Speaking and Teaching: Novartis, Roche, Janssen, Bristol Myers Squibb, Gilead Isabelle Fouchard-Hubert – Speaking and Teaching: JANSSEN Olivier P. Libert – Employment: Gilead Sciences Marie Terrier- Management Position: Gilead Sciences Christiane Stern – Employment: Gilead Sciences Patrick Marcellin – Consulting: Roche, Gilead, BMS, Vertex, Novartis, Janssen-Tibotec, MSD, Boehringer, Pfizer, Abbott, Alios BioPharma; Grant/Research Support: Roche, Gilead, BMS, Novartis, Janssen-Tibotec, MSD, Alios BioPharma; Speaking and Teaching: Roche, Gilead, BMS, Vertex, Novartis, Janssen-Tibotec, 上海皓元 MSD, Abbott The following people have nothing to disclose: Ghassan Riachi, Bruno Roche, Hervé Desmorat, Thierry Constant, Jean françois D. Cadranel, Denis Ouzan Background and aim; Non-invasive methods are therefore becoming increasingly important in the assessment of liver histopathology in CHB patients. One of such techniques is LSM performed with transient elastography (TE). In this study we compared pre-treatment liver histology and liver LSM results of CHB patients, and we evaluated the five-year prognostic value of LSM in CHB patients.

37 Of note, TGFβ is a multifunctional cytokine with the unique ability to direct T cell lineage commitment toward either proinflammatory Th17 T cells or antiinflammatory Treg, depending on the presence of additional factors, such as IL-6.26 Significantly, TGFβ is also a key cytokine driving liver fibrogenesis.27 Disruption of the local balance between opposing effects of TGFβ on liver inflammation and fibrogenesis could underline fibrosis

progression in CHC. Here we found that TGFβ produced by HCV-specific T cells significantly masks T-cell effector response only in those patients who show attenuated fibrosis progression. In addition, TGFβ inversely correlated Selleckchem CHIR-99021 not only with liver inflammation, but also with liver fibrosis progression and fibrogenic hepatic stellate cell (HSC) gene expression.

It is possible that in chronic HCV infection immunoregulatory and antiinflammatory functions of TGFβ, produced by certain HCV-specific Treg, ameliorate liver inflammation, while limiting the fibrotic process. Blood and matched liver biopsy samples were assayed from 19 subjects with CHC who were undergoing routine diagnostic evaluation and who had previously another liver biopsy (Table 1). No patients were being treated for HCV infection. All subjects were HCV RNA+, but none were decompensated. Persons with other forms of liver disease, including due to hepatitis B virus or alcohol, other immunosuppressive conditions, or other comorbidity requiring immunosuppressive therapy were excluded, as were this website subjects with human immunodeficiency virus (HIV) infection. The protocol was reviewed by the Beth Israel Deaconess Medical Center Investigational Review Board and all subjects gave informed consent. Histology of 上海皓元 adequate liver biopsies were staged and graded by both Ishak and Metavir scoring systems and histological activity index (HAI) calculated as total score (grade+stage). Liver fibrosis progression rate was calculated based on histological

staging as the difference in Metavir stage between two biopsies divided by years between biopsies. Establishing the cutoff rate of liver fibrosis progression at >0.1 Metavir-units/year for relatively rapid progression allowed studying subjects as two groups: rapid and slow progressors (Table 1). Extracted PBMC25 and expanded IHL28 were viably cryopreserved for later use. IHLs were expanded using CD3 monoclonal antibody (mAb) (gift of J. Wong, MGH/Boston) to uniformly expand T cells. Autologous Epstein-Barr virus (EBV)-transformed B cell lines (B-LCL) were prepared as described28 for use as antigen-presenting cells for assaying expanded IHL. Two sets of synthetic peptides were used to stimulate PBMC and IHL. Set 1 consisted of 29 18-mer peptides spanning the entire HCV-Core region derived from HCV type 1a strain H77 (BEI resources). Although Core protein has been reported to have immunosuppressive properties,29 peptides stimulate CD8 and CD4 cells, but cannot exhibit Core protein function.

37 Of note, TGFβ is a multifunctional cytokine with the unique ability to direct T cell lineage commitment toward either proinflammatory Th17 T cells or antiinflammatory Treg, depending on the presence of additional factors, such as IL-6.26 Significantly, TGFβ is also a key cytokine driving liver fibrogenesis.27 Disruption of the local balance between opposing effects of TGFβ on liver inflammation and fibrogenesis could underline fibrosis

progression in CHC. Here we found that TGFβ produced by HCV-specific T cells significantly masks T-cell effector response only in those patients who show attenuated fibrosis progression. In addition, TGFβ inversely correlated Saracatinib purchase not only with liver inflammation, but also with liver fibrosis progression and fibrogenic hepatic stellate cell (HSC) gene expression.

It is possible that in chronic HCV infection immunoregulatory and antiinflammatory functions of TGFβ, produced by certain HCV-specific Treg, ameliorate liver inflammation, while limiting the fibrotic process. Blood and matched liver biopsy samples were assayed from 19 subjects with CHC who were undergoing routine diagnostic evaluation and who had previously another liver biopsy (Table 1). No patients were being treated for HCV infection. All subjects were HCV RNA+, but none were decompensated. Persons with other forms of liver disease, including due to hepatitis B virus or alcohol, other immunosuppressive conditions, or other comorbidity requiring immunosuppressive therapy were excluded, as were LBH589 subjects with human immunodeficiency virus (HIV) infection. The protocol was reviewed by the Beth Israel Deaconess Medical Center Investigational Review Board and all subjects gave informed consent. Histology of medchemexpress adequate liver biopsies were staged and graded by both Ishak and Metavir scoring systems and histological activity index (HAI) calculated as total score (grade+stage). Liver fibrosis progression rate was calculated based on histological

staging as the difference in Metavir stage between two biopsies divided by years between biopsies. Establishing the cutoff rate of liver fibrosis progression at >0.1 Metavir-units/year for relatively rapid progression allowed studying subjects as two groups: rapid and slow progressors (Table 1). Extracted PBMC25 and expanded IHL28 were viably cryopreserved for later use. IHLs were expanded using CD3 monoclonal antibody (mAb) (gift of J. Wong, MGH/Boston) to uniformly expand T cells. Autologous Epstein-Barr virus (EBV)-transformed B cell lines (B-LCL) were prepared as described28 for use as antigen-presenting cells for assaying expanded IHL. Two sets of synthetic peptides were used to stimulate PBMC and IHL. Set 1 consisted of 29 18-mer peptides spanning the entire HCV-Core region derived from HCV type 1a strain H77 (BEI resources). Although Core protein has been reported to have immunosuppressive properties,29 peptides stimulate CD8 and CD4 cells, but cannot exhibit Core protein function.

001). Treatment response was not affected by prior HBV treatment. Furthermore, no resistance Crizotinib to tenofovir DF developed through

week 72. Among patients with an alanine aminotransferase (ALT) greater than the upper limit of normal at baseline, normalization of ALT occurred in 74% of patients receiving tenofovir DF and 31% of patients receiving placebo (P < 0.001). The rate of grade 3/4 adverse events was higher among patients treated with placebo (24%) than patients treated with tenofovir DF (10%). No patients met the safety endpoint of a 6% decrease in spine bone mineral density at week 72. The authors concluded that tenofovir DF therapy in HBV-infected adolescents was well tolerated and highly effective at suppressing HBV DNA and normalizing ALT values in both treatment-naïve adolescents and those with prior exposure to HBV therapy. There are several potential limitations of this study. Most of the subjects enrolled in this study were Caucasian patients from Poland and had HBV genotypes A and D. In the

United States, genotypes A and C are most common, so whether these results translate into similar findings in adolescents with genotype click here C is currently unknown.2 Tenofovir DF has been associated with decreased bone density and osteoporotic fracture risk in human immunodeficiency virus–positive patients.3 Over 72 weeks of therapy, no significant decrease in spine bone mineral density was observed, but whether this observation will persist in adolescents with chronic HBV after a longer period of use of tenofovir DF is not known. ALT, alanine aminotransferase; DF, disoproxil fumarate;

HBV, hepatitis B virus. It is quite gratifying to witness the continued pipeline of pharmaceuticals to combat HBV infection being studied and ultimately receiving approval for use in children and adolescents. It was not that long ago that there were no approved medications medchemexpress or very few limited drugs to treat HBV. Although universal use of HBV vaccine will ultimately prove to be the single greatest public health measure to combat chronic HBV infection, for those unfortunate children and adolescents afflicted with the disease, medications such as tenofovir DF hold the promise of allowing long and healthy lives. Although this study was limited to adolescents, future study of tenofovir DF in younger children is being initiated.

The efficacy of pantoprazole

magnesium was compared with that of esomeprazole over 4 and 8 weeks’ treatment in patients with erosive gastroesophageal reflux disease (GERD). Methods: In this multicentre (14 Brazilian sites), phase III, double-blind study, patients with erosive GERD (Los Angeles grades A–D) were randomised to pantoprazole magnesium (n = 290) or esomeprazole (n = 288), both administered at 40 mg once daily for 8 weeks. Severity of esophagitis (at endoscopy) and GERD-related symptoms (using ReQuest™-GI) were assessed at baseline and 4 and 8 weeks, and complete remission (a ReQuest™-GI score below 1.73 RG7204 nmr plus endoscopically confirmed healing) was compared between treatments (significance p < 0.05). Results: Complete remission with pantoprazole magnesium was non-inferior to that with esomeprazole at 4 and 8 weeks (table). Mucosal healing was similar for the two treatments. However, symptom relief with pantoprazole magnesium was significantly greater at 8 weeks (p = 0.0370) than that with esomeprazole. Both PPIs had similarly low rates of adverse events. Conclusion: Pantoprazole magnesium 40 mg was as effective as esomeprazole 40 mg for complete remission and mucosal healing, but provided greater symptom relief at 8 weeks, suggesting an

extended period of treatment effect. Key Word(s): 1. GERD; 2. Symptom relief; 3. Pantoprazole; 4. Esomeprazole; Complete remission, endotcopically confirmed healing and symptom relief rates after 4 and 8 weeks (intent-to-trcat population) Assessment 4 weeks, n (%) 8 weeks, n(%) Pantoprazole magnesium Esomeprazole Abiraterone Pantoprazole magnesium medchemexpress Esomeprazole *P = 0.0370 versus esomeprazole. Presenting Author: RAPAT PITTAYANON Additional Authors: RATHA-KORN VILAICHONE, TANISA PATCHARATRAKUL, CHINNAVAT SUTTHIVANA, WANIT PIYANIRUN, MONTIRA MANEERATANAPORN, SOMCHAI LEELAKUSOLVONG,

UDOM KACHINTORN, SUTEP GONLACHANVIT, VAROCHA MAHACHAI Corresponding Author: RAPAT PITTAYANON Affiliations: Chulalongkorn University; Thammasart University; Bhumipol Adulyadej Hospital; Pramongkulklao Hospital; Siriraj Hospital, Mahidol University Objective: Introduction: The awareness of gastroesophageal reflux disease (GERD) has led to an increased prevalence of GERD across the Asian region. It has a significant impact on quality of life and health care expenditure. Proton pump inhibitor (PPI) is commonly used to relief the symptoms. The aim of this study was to understand the patient perception on GERD, its impact on quality of life and the pattern of PPI use in GERD patients in Thailand. Methods: Methods: The physician-diagnosed GERD patients recruited from hospitals throughout Thailand participated in the 20 minute face-to-face interviews after signing informed consent. Results: Results: A total of 400 patients from 39 hospitals were enrolled.

The efficacy of pantoprazole

magnesium was compared with that of esomeprazole over 4 and 8 weeks’ treatment in patients with erosive gastroesophageal reflux disease (GERD). Methods: In this multicentre (14 Brazilian sites), phase III, double-blind study, patients with erosive GERD (Los Angeles grades A–D) were randomised to pantoprazole magnesium (n = 290) or esomeprazole (n = 288), both administered at 40 mg once daily for 8 weeks. Severity of esophagitis (at endoscopy) and GERD-related symptoms (using ReQuest™-GI) were assessed at baseline and 4 and 8 weeks, and complete remission (a ReQuest™-GI score below 1.73 KPT330 plus endoscopically confirmed healing) was compared between treatments (significance p < 0.05). Results: Complete remission with pantoprazole magnesium was non-inferior to that with esomeprazole at 4 and 8 weeks (table). Mucosal healing was similar for the two treatments. However, symptom relief with pantoprazole magnesium was significantly greater at 8 weeks (p = 0.0370) than that with esomeprazole. Both PPIs had similarly low rates of adverse events. Conclusion: Pantoprazole magnesium 40 mg was as effective as esomeprazole 40 mg for complete remission and mucosal healing, but provided greater symptom relief at 8 weeks, suggesting an

extended period of treatment effect. Key Word(s): 1. GERD; 2. Symptom relief; 3. Pantoprazole; 4. Esomeprazole; Complete remission, endotcopically confirmed healing and symptom relief rates after 4 and 8 weeks (intent-to-trcat population) Assessment 4 weeks, n (%) 8 weeks, n(%) Pantoprazole magnesium Esomeprazole PLX4720 Pantoprazole magnesium MCE Esomeprazole *P = 0.0370 versus esomeprazole. Presenting Author: RAPAT PITTAYANON Additional Authors: RATHA-KORN VILAICHONE, TANISA PATCHARATRAKUL, CHINNAVAT SUTTHIVANA, WANIT PIYANIRUN, MONTIRA MANEERATANAPORN, SOMCHAI LEELAKUSOLVONG,

UDOM KACHINTORN, SUTEP GONLACHANVIT, VAROCHA MAHACHAI Corresponding Author: RAPAT PITTAYANON Affiliations: Chulalongkorn University; Thammasart University; Bhumipol Adulyadej Hospital; Pramongkulklao Hospital; Siriraj Hospital, Mahidol University Objective: Introduction: The awareness of gastroesophageal reflux disease (GERD) has led to an increased prevalence of GERD across the Asian region. It has a significant impact on quality of life and health care expenditure. Proton pump inhibitor (PPI) is commonly used to relief the symptoms. The aim of this study was to understand the patient perception on GERD, its impact on quality of life and the pattern of PPI use in GERD patients in Thailand. Methods: Methods: The physician-diagnosed GERD patients recruited from hospitals throughout Thailand participated in the 20 minute face-to-face interviews after signing informed consent. Results: Results: A total of 400 patients from 39 hospitals were enrolled.

15 Recall bias remains the main criticism of studies designed to retrospectively evaluate this website childhood exposures. Currently in progress are several prospective

studies designed to evaluate the genetic make-up, bacterial flora, immune function, biomarkers and environmental exposures of individuals at risk of developing IBD. The European Crohn’s and Colitis Organisation’s ‘ORIGIN’ (observing relatives, immunity, genetics and the microbiome before the onset of Crohn’s disease) project aims to prospectively recruit 6500 first-degree healthy relatives of probands with CD from 16 European countries and follow them for 10 years or more. An estimated rate of 0.13% new cases of CD is expected per year. Prospectively-collected data derived from questionnaires on diet and environmental exposures should minimize recall bias and missing data. Overall, this paper allows clinicians to provide evidence-based exposure risks to IBD patients. The safety of immunization and reduced risk of UC following immunization against mumps is particularly reassuring. Breast-feeding

for at least 3–6 months should be encouraged especially for infants with a strong family GSI-IX history of IBD. “
“I read with interest the article by Garg et al.,1 who showed that tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B virus (HBV) presenting as acute-on-chronic liver failure (ACLF). As indicated by the authors, the short-term prognosis of patients with spontaneous medchemexpress severe acute exacerbation of chronic hepatitis B leading to ACLF-like presentation is extremely poor, with a mortality rate ranging

from 30%-70%. The current study showed that mortality rate was 43% in the tenofovir group and up to 85% in the placebo group. Prior to the start of the trial by Garg et al., Chien et al.2 demonstrated that the use of lamivudine is definitely beneficial for these patients, with an improved survival compared to historic controls. Moreover, this study showed that patients with serum bilirubin lower than 20 mg/dL could usually be rescued with the use of lamivudine. As a consequence, the HBV management guidelines proposed by organizations such as the Asian Pacific Association for the Study of the Liver (APASL)3 as well as the American Association for the Study of Liver Diseases (AASLD)4 consistently recommend that when patients with HBV who have ACLF are treated, antiviral drugs should be promptly instituted. The trial by Garg et al., which used placebo drug as a control, leading to an appreciably high mortality in this group, in order to demonstrate the efficacy of tenofovir in treating patients with HBV who have ACLF, was apparently medically unethical. Similar studies should be strongly discouraged. Gin-Ho Lo M.D.*, * Department of Medical Education, Digestive Center, E-Da Hospital, I-Shou University, Kaohsiung City, Taiwan.

15 Recall bias remains the main criticism of studies designed to retrospectively evaluate selleck inhibitor childhood exposures. Currently in progress are several prospective

studies designed to evaluate the genetic make-up, bacterial flora, immune function, biomarkers and environmental exposures of individuals at risk of developing IBD. The European Crohn’s and Colitis Organisation’s ‘ORIGIN’ (observing relatives, immunity, genetics and the microbiome before the onset of Crohn’s disease) project aims to prospectively recruit 6500 first-degree healthy relatives of probands with CD from 16 European countries and follow them for 10 years or more. An estimated rate of 0.13% new cases of CD is expected per year. Prospectively-collected data derived from questionnaires on diet and environmental exposures should minimize recall bias and missing data. Overall, this paper allows clinicians to provide evidence-based exposure risks to IBD patients. The safety of immunization and reduced risk of UC following immunization against mumps is particularly reassuring. Breast-feeding

for at least 3–6 months should be encouraged especially for infants with a strong family Alectinib cell line history of IBD. “
“I read with interest the article by Garg et al.,1 who showed that tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B virus (HBV) presenting as acute-on-chronic liver failure (ACLF). As indicated by the authors, the short-term prognosis of patients with spontaneous MCE severe acute exacerbation of chronic hepatitis B leading to ACLF-like presentation is extremely poor, with a mortality rate ranging

from 30%-70%. The current study showed that mortality rate was 43% in the tenofovir group and up to 85% in the placebo group. Prior to the start of the trial by Garg et al., Chien et al.2 demonstrated that the use of lamivudine is definitely beneficial for these patients, with an improved survival compared to historic controls. Moreover, this study showed that patients with serum bilirubin lower than 20 mg/dL could usually be rescued with the use of lamivudine. As a consequence, the HBV management guidelines proposed by organizations such as the Asian Pacific Association for the Study of the Liver (APASL)3 as well as the American Association for the Study of Liver Diseases (AASLD)4 consistently recommend that when patients with HBV who have ACLF are treated, antiviral drugs should be promptly instituted. The trial by Garg et al., which used placebo drug as a control, leading to an appreciably high mortality in this group, in order to demonstrate the efficacy of tenofovir in treating patients with HBV who have ACLF, was apparently medically unethical. Similar studies should be strongly discouraged. Gin-Ho Lo M.D.*, * Department of Medical Education, Digestive Center, E-Da Hospital, I-Shou University, Kaohsiung City, Taiwan.

The variability of the inhibitor assay is partly caused by variations in the FVIII activity assays because of aberrant liquid handling. Further standardization of the methods is needed to improve these figures. The author stated that he had no interests which might be perceived as posing Talazoparib ic50 a conflict or bias. “
“Formal assessment of outcome in hemophilia using validated instruments is being increasingly required to document and report effectiveness of treatment protocols. As new treatment regimens and approaches to prophylaxis

evolve, it is important that hemophilia care teams become familiar with these tools. In the past, this was done with the clinical and radiologic joint scores. While these scores are useful in assessing the structure and function of a joint, they do not consider the impact of arthropathy on overall musculoskeletal function. They are also not capable of assessing the efficacy of therapeutic Selleckchem Ixazomib interventions on function. The development of newer instruments that assess overall musculoskeletal function has added a new dimension to this field. Quality of life measurements have also been widely used in the last few years. This chapter describes the use of these clinimetric instruments as well as their psychometric properties and limitations. An improved understanding of

these tools should help increase their utilization in clinical practise and the data collected would help decide suitability of treatment protocols “
“This chapter contains section titles: Prothrombin Deficiency Factor V Deficiency Factor VII Deficiency Factor X Deficiency Factor XI Deficiency Factor

XIII Deficiency Combined Factor V and Factor VIII Deficiency Glanzmann Thrombaesthenia Gardner–Diamond Syndrome and von Willebrand Disease Qualitative Platelet Disorder “
“Summary.  Little is known about the relative importance of factor VIII (FVIII) treatment attributes to haemophilia A patients and their willingness to accept trade-offs among these attributes. To quantify patient and parent preferences 上海皓元 for FVIII treatments and compare the relative importance of treatment attributes. Adult patients and parents of children with severe haemophilia A in the US completed a web-enabled, choice-format conjoint survey that presented a series of 12 trade-off questions, each including a pair of hypothetical treatment profiles. Each profile was defined by percent of bleeds stopped with one or two infusions, chance of developing an inhibitor, risk of viral infection, preparation volume, dosage strengths available, and history of supply shortage. Trade-off questions were based on a D-optimal experimental design. Preference weights for attribute levels were estimated using random-parameters logit. One hundred and forty seven subjects completed the survey. Over the ranges of attribute levels included in the study, risk of viral infection was the most important attribute.

We excluded patients with viral hepatitis and other concomitant liver diseases. The XL probe was used in case M probe measurements failed because of obesity. Hepatic steatosis was graded by CAP using the M probe according to published cutoffs (S1=222-232; S2=233-289; S3=290 dB/m or above). Probe-specific cutoffs were used to define F3-4 and F4. We followed the manufacturer’s reliability

criteria based on the number of valid acquisitions and the interquartile range (IQR)-to-median ratio. Results: 2080 patients (45.4% women) find more completed the examination. M probe measurements were successful in 1927 (92.6%) patients, and the mean CAP was 262±65 dB/m (IQR 216-313). 1402 patients had fatty liver (72.8%; 95% CI 70.8-74.7). The number of patients with S1, S2 and S3 was 96 (5.0%), 574 (29.8%) and 732 (38.0%), respectively. LS by M probe

were reliable in 1908 of 2080 (91.7%) patients, and the mean LS was 7.5±5.3 kPa (IQR 4.8-8.2). A further 123 patients underwent XL probe examination and had reliable LS which was 9.2±10.0 kPa (IQR 4.4-9.5). Combining the reliable results by either probe in 2031 (97.6%) patients, 348 (17.1%, 95% CI 15.5-18.8%) had F3-4 and 233 (11.5%, 95% CI 10.1-12.9%) had F4. F4 was found in 4.8%, 6.3%, 7.0% and 18.9% of patients with S0, S1, S2 and S3, respectively (P<0.001). Conclusions: Patients with type 2 diabetes have a high prevalence of fatty liver and cirrhosis. Our data support fatty liver and fibrosis screening in this high-risk group. [This work was substantially supported by a grant DNA Damage inhibitor from the Research Grants Council of Hong Kong (Project no. CUHK 477813).] Disclosures: Grace LH Wong – Advisory Committees or Review Panels: Otsuka, Gilead; Speaking and Teaching: Echosens, Furui, Gilead, Janssen, Bristol-Myers Squibb, Otsuka Henry Lik-Yuen Chan – Advisory Committees or Review Panels: Gilead, MSD, Bristol-Myers Squibb, Roche, Novartis MCE公司 Pharmaceutical; Speaking and Teaching: Echosens, Abbvie Vincent

W. Wong – Advisory Committees or Review Panels: Abbvie, Gilead; Consulting: Merck, NovaMedica; Speaking and Teaching: Gilead, Echosens The following people have nothing to disclose: Raymond Kwok, Juliana C. Chan, Alice P. Kong Background: Nonalcoholic steatohepatitis (NASH) is associated with an increased risk of cardiovascular disease (CVD) mortality following liver transplant (LT); however, predictors of these events are unknown. Aim: To assess predictors of post-LT CVD mortality in patients with NASH. Methods: A cohort of 5,469 adults with NASH who underwent first LT (excluding status 1) from 2/2002-12/2011 was identified in the Organ Procurement and Transplantation Network database. An independent physician panel reviewed recipient cause of death. Cox proportional hazard model and Kaplan-Meier method assessed CVD mortality, defined as primary cause of death from thromboembolism, arrhythmia, heart failure, myocardial infarction, cardiac arrest and/or stroke.